13.48
price down icon6.65%   -0.96
after-market 시간 외 거래: 13.50 0.02 +0.15%
loading
전일 마감가:
$14.44
열려 있는:
$13.98
하루 거래량:
983.56K
Relative Volume:
1.03
시가총액:
$1.26B
수익:
$288.00K
순이익/손실:
$-228.06M
주가수익비율:
-3.1718
EPS:
-4.25
순현금흐름:
$-168.82M
1주 성능:
-12.81%
1개월 성능:
-13.20%
6개월 성능:
-40.75%
1년 성능:
-23.02%
1일 변동 폭
Value
$13.23
$13.98
1주일 범위
Value
$13.23
$15.44
52주 변동 폭
Value
$11.40
$27.20

Viridian Therapeutics Inc Stock (VRDN) Company Profile

Name
명칭
Viridian Therapeutics Inc
Name
전화
617.272.4600
Name
주소
221 CRESCENT STREET, WALTHAM
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
VRDN's Discussions on Twitter

VRDN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VRDN
Viridian Therapeutics Inc
13.48 1.26B 288.00K -228.06M -168.82M -4.25
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-19 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-11-25 개시 TD Cowen Buy
2024-09-11 재확인 Needham Buy
2024-06-11 개시 Wolfe Research Outperform
2024-06-06 개시 Goldman Buy
2024-05-09 다운그레이드 B. Riley Securities Buy → Neutral
2024-05-09 다운그레이드 Ladenburg Thalmann Buy → Neutral
2023-06-14 개시 BTIG Research Buy
2023-06-14 재개 Credit Suisse Outperform
2023-05-30 개시 RBC Capital Mkts Outperform
2023-04-17 개시 Wells Fargo Overweight
2023-03-30 개시 Stifel Buy
2022-12-19 개시 Cowen Outperform
2022-12-19 개시 Needham Buy
2022-12-16 개시 Credit Suisse Outperform
2022-12-01 개시 H.C. Wainwright Buy
2022-06-23 개시 B. Riley Securities Buy
2021-11-18 개시 SVB Leerink Outperform
2021-10-12 개시 Evercore ISI Outperform
2021-01-25 개시 Ladenburg Thalmann Buy
모두보기

Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스

pulisher
03:58 AM

Quantbot Technologies LP Invests $164,000 in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

03:58 AM
pulisher
Mar 28, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Swiss National Bank - Defense World

Mar 28, 2025
pulisher
Mar 25, 2025

Raymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Where are the Opportunities in (VRDN) - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 22, 2025

Charles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

AlphaQuest LLC Acquires 1,519 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Commit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using Options - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon Corp - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Arizona State Retirement System - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 15, 2025
pulisher
Mar 15, 2025

410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc. - Defense World

Mar 15, 2025
pulisher
Mar 12, 2025

Viridian Therapeutics at Leerink’s Conference: Progress in TED Treatments By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Viridian Therapeutics appoints new director, sees board resignation - Investing.com India

Mar 10, 2025
pulisher
Mar 06, 2025

What is B. Riley’s Forecast for VRDN Q1 Earnings? - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Principal Financial Group Inc. Has $3.42 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

What is B. Riley’s Estimate for VRDN Q2 Earnings? - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Terminates Prior $175 Million Sale Agreement -March 04, 2025 at 06:36 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Enters New $300M Sale Agreement - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics inks new $300M sales agreement - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Rhumbline Advisers Has $1.92 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

Q1 EPS Estimates for Viridian Therapeutics Raised by Wedbush - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

How to Take Advantage of moves in (VRDN) - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 02, 2025

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window - Seeking Alpha

Mar 02, 2025
pulisher
Mar 02, 2025

FY2027 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics (NASDAQ:VRDN) Posts Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains OutperformSpeculative Risk Rating - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Feb 28, 2025
pulisher
Feb 28, 2025

Viridian Therapeutics Reports Strong Progress and Financials - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics reports Q4 EPS (81c), consensus ($1.04) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Positioned for Market Leadership with Strategic Advancements and Competitive Edge - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

VRDNViridian Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics: Strong TED Trial Results and Promising Pipeline Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics' Q4 Net Loss Narrows, Revenue Flat -February 27, 2025 at 09:27 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Revenue $72,000 -February 27, 2025 at 07:20 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Earnings Flash (VRDN) Viridian Therapeutics Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $1.05 Loss - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Feb 27, 2025
pulisher
Feb 25, 2025

Viridian Therapeutics Becomes Oversold (VRDN) - Nasdaq

Feb 25, 2025
pulisher
Feb 23, 2025

Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Tuesday - Defense World

Feb 23, 2025
pulisher
Feb 23, 2025

Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat

Feb 23, 2025

Viridian Therapeutics Inc (VRDN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):